Latest News

  • Alkermes to Host Conference Call to Discuss First Quarter 2014 Financial Results Read More
  • Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil for Treatment of Schizophrenia Read More
  • Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder Read More

Investors

Learn More

Working at Alkermes

Join Our Team